Patents by Inventor Philippe Mondon

Philippe Mondon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9737476
    Abstract: The present invention proposes an extract of Albizia Julibrissin for the cosmetic treatment of skin glycation. The extract is preferably obtained from flowers and/or seeds. Application to cosmetic formulations for treating cutaneous fatigue, in particular for improving the radiance of skin and eye contour (under eye bags and dark circles) and for treating the loss of skin suppleness. A preferred composition, particularly adapted for eye contour, comprises the Albizia Julibrissin extract combined with Darutoside that can be extracted from Siegesbeckia Orientalis.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: August 22, 2017
    Assignee: Sederma
    Inventors: Arnaud Fournial, Claire-Marie Grizaud, Philippe Mondon
  • Publication number: 20170157014
    Abstract: The peptides have the general following formula: X-Pro*-Pro*-Xaa-Y in which: —Xaa is selected from Leucine (Leu, L), Arginine (Arg, R), Lysine (Lys, K), Alanine (Ala, A), Serine (Ser, S), and Aspartic acid (Asp, D); —At the N terminal end of the peptide, X is selected from H, —CO—R1 and —SO2—R1; —At the C terminal end of the peptide, Y is selected from OH, OR1, NH2, NHR1 and NR1R2; —R1 and R2 are, independently from each other, selected from an alkyle, aryle, aralkyle, alkylaryl, alkoxy and aryloxy group, that can be linear, branched, cyclic, poly-cyclic, non-saturated, hydroxylated, carbonylated, phosphorylated and/or sulfured, and which skeletum can comprise an heteroatom, in particular an O, S and/or N atom; —Pro* correspond to a Proline, an analogue or derivative thereof; —if X is H then Y is selected from OR1, NH2, NHR1 and NR1R2, and if Y is OH then X is —CO— or —SO2—R1; and the peptide hypoxanthine-Pro-Pro-Arg being excluded.
    Type: Application
    Filed: May 21, 2015
    Publication date: June 8, 2017
    Applicant: SEDERMA
    Inventors: OLIVIER PESCHARD, ANNE DOUCET, RICHARD LEROUX, PHILIPPE MONDON
  • Publication number: 20170071844
    Abstract: The invention is directed to the use of at least one peptide of formula: X-(Xaa1)n-Pro*-(Xaa2)m-Y (I) With: —n=0, 1 or 2; -m=0 or 1 and if m=0 then n?0-Xaa1 is: -An hydrophobic aminoacid selected from Alanine (Ala, A), Valine (Val, V), Methionine (Met, M), Leucine (Leu, L), Isoleucine (Ile, I), Phenylalanine (Phe, F), Proline (Pro, P) and analogues and derivatives thereof; —A polar aminoacid selected from Serine (Ser, S), Threonine (Thr, T), Tyrosine (Tyr, Y), Asparagine (Asn, N), Glutamine (Gln, Q) and analogues and derivatives thereof; —or Glycine (Gly, G); When n=2 the two aminoacids Xaa1 can be the same or different; -Xaa2 is: —An hydrophobic aminoacid selected from Alanine (Ala, A), Valine (Val, V), Methionine (Met, M), Leucine (Leu, L), Isoleucine (Ile, I), Phenylalanine (Phe, F), Proline (Pro, P) and analogues and derivatives thereof; —A basic aminoacid selected from Arginine (Arg, R), Lysine (Lys, K) and Histidine (His, H) and analogues and derivatives thereof; —Glycine (Gly, G) or Serine (Ser, S); —A
    Type: Application
    Filed: November 28, 2016
    Publication date: March 16, 2017
    Applicant: Sederma
    Inventors: Olivier Peschard, Philippe Mondon
  • Patent number: 9534015
    Abstract: The invention is directed to the use of at least one peptide of formula: X-(Xaa1)n-Pro*-(Xaa2)m-Y (I) With: ?n=0, or 2; ?m=0 or 1 and if m=0 then n?0?Xaa is: —An hydrophobic aminoacid; —A polar aminoacid; or —Glycine (Gly, G); When n=2 the two aminoacids Xaa1 can be the same or different; —Xaa2 is: —An hydrophobic amino acid; —A basic aminoacid; —Glycine (Gly, G) or Serine (Ser, S); —At the N terminal end of the peptide, X is selected from H, —CO—R1 and —SO2—R1; —At the C terminal end of the peptide, Y is selected from OH, OR1, NH2, NHR1 or NR1R2, —R1 and R2 being independently from each other, selected from an alkyle, aryle, aralkyle, alkylaryl, alkoxy and aryloxy group; —Pro* Excluding the peptides where X=H and Y=OH, for a non therapeutical cosmetic pro-pigmenting treatment of skin.
    Type: Grant
    Filed: November 25, 2013
    Date of Patent: January 3, 2017
    Assignee: Sederma
    Inventors: Olivier Peschard, Philippe Mondon
  • Patent number: 9346883
    Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: May 24, 2016
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Gamamabs Pharma SA
    Inventors: Abdelhakim Kharrat, Olivier Dubreuil, Yassamine Lazrek, Philippe Mondon, Khalil Bouayadi, Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege A. Gaborit
  • Publication number: 20150274776
    Abstract: The invention is directed to the use of at least one peptide of formula: X-(Xaa1)n-Pro*-(Xaa2)m-Y (I) With: —n=0, or 2; —m=0 or land if m=0 then n?0 —Xaa is: —An hydrophobic aminoacid selected from Alanine (Ala, A), Valine (Val, V), Methionine (Met, M), Leucine (Leu, L), Isoleucine (Ile, I), Phenylalanine (Phe, F), Proline (Pro, P) and analogues and derivatives thereof; —A polar aminoacid selected from Serine (Ser, S), Threonine (Thr, T), Tyrosine (Tyr, Y), Asparagine (Asn, N), Glutamine (Gln, Q) and analogues and derivatives thereof; or —Glycine (Gly, G); When n=2 the two aminoacids Xaa1 can be the same or different; —Xaa2 is: —An hydrophobic aminoacid selected from Alanine (Ala, A), Valine (Val, V), Methionine (Met, M), Leucine (Leu, L), Isoleucine (Ile, I), Phenylalanine (Phe, F), Proline (Pro, P) and analogues and derivatives thereof; —A basic aminoacid selected from Arginine (Arg, R), Lysine (Lys, K) and Histidine (His, H) and analogues and derivatives thereof; —Glycine (Gly, G) or Serine (Ser, S); —At t
    Type: Application
    Filed: November 25, 2013
    Publication date: October 1, 2015
    Applicant: SEDERMA
    Inventors: Olivier Peschard, Philippe Mondon
  • Patent number: 9126060
    Abstract: Geranylgeranyl-2-propanol compound (GGP) having the following formula I: is proposed for use according to the present invention as a cosmetic active compound for the prevention and treatment of aging of skin and its appendages. The GGP has a protective action against oxidative stress and free radical, on telomeres and on mitochondria and its activity. In particular, GGP can be used for the treatment of wrinkles, fine lines and visible discontinuities of skin, for the treatment pigmentation disorders.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: September 8, 2015
    Assignee: SEDERMA
    Inventors: Arnaud Fournial, Philippe Mondon, Olivier Peschard
  • Publication number: 20150196475
    Abstract: The present invention relates to the field of cosmetic and dermopharmaceutical compositions. It concerns oligomer compounds of D-glucuronic acid or D-glucuronate with a ? (1-4) sequence (or oligoglucuronans) containing a degree of acetylation specifically between 8.7±0.5 and 9.2±0.5% by weight of O—CO—CH3 group compared to the weight of glucuronic acid and with a degree of polymerisation (DP) of 18-19±2. The oligomer compounds according to the present invention are intended to stimulate the elasticity of the dermis and epidermis although they also act to increase dermo-epidermal cohesion in order to combat skin ageing, lines, wrinkles, visible and/or tactile skin discontinuities, loss of firmness, elasticity and tone and to combat skin tissue deformability. The invention also concerns a cosmetic composition containing at least one compound as recited according to the present invention.
    Type: Application
    Filed: March 23, 2015
    Publication date: July 16, 2015
    Inventors: Arnaud Fournial, Claire-Marie Grizaud, Caroline Le Moigne, Philippe Mondon
  • Patent number: 9050477
    Abstract: The present invention related to cosmetic compositions comprising oridonin and new cosmetic uses. Oridonin is used for fighting the signs of cutaneous aging and for slimming. A composition comprising a combination of oridonin and darutigenol or a derivative thereof, in particular darutoside, is disclosed together with the cosmetic use of such composition.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: June 9, 2015
    Assignee: SEDERMA
    Inventors: Arnaud Fournial, Philippe Mondon
  • Publication number: 20150017269
    Abstract: The present invention proposes an extract of Albizia Julibrissin for the cosmetic treatment of skin glycation. The extract is preferably obtained from flowers and/or seeds. Application to cosmetic formulations for treating cutaneous fatigue, in particular for improving the radiance of skin and eye contour (under eye bags and dark circles) and for treating the loss of skin suppleness. A preferred composition, particularly adapted for eye contour, comprises the Albizia Julibrissin extract combined with Darutoside that can be extracted from Siegesbeckia Orientalis.
    Type: Application
    Filed: September 27, 2012
    Publication date: January 15, 2015
    Applicant: SEDERMA
    Inventors: Arnaud Fournial, Claire-Marie Grizaud, Philippe Mondon
  • Publication number: 20140378663
    Abstract: A method for producing a variant of a parent polypeptide including a Fc region, which variant exhibits reduced binding to the protein C1q and to at least one receptor Fcg? R as compared to the parent polypeptide.
    Type: Application
    Filed: June 25, 2012
    Publication date: December 25, 2014
    Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DE BIOTECHNOLOGIES
    Inventors: Alexandre Fontayne, Sylvie Jorieux, Celine Monnet-Mars, Philippe Mondon, Abdelhakim Kharrat, Khalil Bouayadi
  • Patent number: 8741357
    Abstract: The invention provides a cosmetic or dermopharmaceutic composition containing an Euglena extract, its use to activate the cellular metabolism and in particular to protect and/or improve the state of the skin and to reduce the signs of ageing in particular and/or cutaneous fatigue.
    Type: Grant
    Filed: January 13, 2006
    Date of Patent: June 3, 2014
    Assignee: Sederma SAS
    Inventors: Karl Lintner, Claire Mas Chamberlin, Louis François Lamy, Philippe Mondon
  • Patent number: 8742074
    Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: June 3, 2014
    Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: Christian Behrens, Sylvie Jorieux, Abdelhakim Kharrat, Khalil Bouayadi, Philippe Mondon, Celine Monnet-Mars
  • Publication number: 20140141019
    Abstract: The invention relates to antibodies against HER3 and their use in the treatment of cancer.
    Type: Application
    Filed: May 11, 2012
    Publication date: May 22, 2014
    Applicant: INSERM (INSTITUT NATIONALDE LA SENTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Abdelhakim Kharrat, Olivier Dubreuil, Yassamine Lazrek, Philippe Mondon, Khalil Bouayadi, Thierry Chardes, Andre Pelegrin, Christel Larbouret, Nadege A. Gaborit
  • Patent number: 8697656
    Abstract: The present invention concerns a peptide of following formula I: R being a side chain having at least one heteroatom selected from sulfur, nitrogen and oxygen in a carbonyl form (C?O); R1 being either H or a lipophilic chain; R2 being either OH or a lipophilic chain. More particularly the present invention concerns a cosmetic composition comprising a peptide as recited above and a physiologically acceptable medium. Results on the activity of the compounds are obtained and on the general state of the skin and its appendages, in particular via the stimulation of extracellular matrix components.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: April 15, 2014
    Assignee: SEDERMA
    Inventors: Arnaud Fournial, Philippe Mondon, Olivier Peschard
  • Patent number: 8603498
    Abstract: The compound according to the invention has the following developed formula IX: wherein: X=PO(OH)2; SO2(OH); PO(OH)(Xaa)m or SO2(Xaa)m; A=H; OH; NH2 or akyl (1-6C); n=1 to 4; Y=—CO—OR2; —CO—NR3R4; —O—CO—R2; —C?CR2; R2=an alkyl, aryl, aralkyl, acyl, sulfonyl, sugar or alkoxy chain of 1 to 24 carbon atoms, linear, branched or cyclic, with or without substitutions, saturated or not, hydroxylated or not, sulfurated or not; R5=OH, O-alk (1-6C), (Xaa)m, NH2 or NH-alkyl(1-6C); Xaa=peptide of m aminoacids Xaa with m from 1 to 10; The compound is preferably phosphated, obtained from malic acid and having the following developed formula: A cosmetic composition comprising the compound of the present invention can improve the general condition of the skin, for example hydration, lightening and mechanical properties.
    Type: Grant
    Filed: January 17, 2011
    Date of Patent: December 10, 2013
    Assignee: Sederma, S.A.S.
    Inventors: Arnaud Fournial, Philippe Mondon, Olivier Peschard
  • Publication number: 20130309332
    Abstract: According to the present invention the extract of plant origin of the Globularia genus is used for a non-therapeutic cosmetic treatment of the skin and/or appendages. Preferably the species is Globularia cordifolia and the extract is obtained by in vitro plant culture. The extract can be used in particular for preventing and/or treating skin ageing by stimulating the 10 reactions of detoxification and cellular regeneration through a hormetic type response, for improving the transparency and radiance of complexion, for preventing or treating sensitive and reactive skins, for preventing or treating rednesses, for preventing protein glycation, for increasing and/or maintaining the number of dermal stem cells, for increasing and/or maintaining the dermal macromolecules, in particular collagen and elastin, for increasing the volume of the dermis, for 15 preventing and/or treating fines lines and wrinkles, for firming skin, for preventing hair loss and/or stimulating hair regrowth.
    Type: Application
    Filed: January 30, 2012
    Publication date: November 21, 2013
    Applicant: SEDERMA, S.A.S.
    Inventors: Arnaud Fournial, Claire-Marie Grizaud, Philippe Mondon, Caroline Le Moigne
  • Patent number: 8404648
    Abstract: The invention concerns polypeptides of the general formula (I): A-(Xaa)n-Lys-X-Lys-B wherein: i) A is —NH2, NH3+, or NH-D (D is an acyl group being biotin or an alkyl chain (C2-C22)), H) B is H, O?OR1 or NR2R3 and R1, R2 and R3 independently either: H or an alkyl chain (C1-C24), iii) (Xaa)n is an amino acid chain including any amino acid natural or not, excluding arginine and lysine, iv) “n” is between 0-3, and v) X is either a chain of two any amino acids (Xaa1Xaa2) which may be the same or different, excluding arginine, lysine and excluding Xaa1Xaa2=Thr-Thr, Gly-His and Glu-His, or X is a spacer selected among beta-alanyl, 5-amino-valeroyl, 4-amino-cyclohexanoyl, 4-amino-butyroyl, 6-amino-caproyl and derivatives thereof. More particularly, the invention concerns polypeptides of formula (I) wherein “n” is 0 and with the formula: A-Lys-X-Lys-B; A, X and B being defined herein. Compositions containing at least one of said polypeptides and their use.
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: March 26, 2013
    Assignee: Sederma
    Inventors: Karl Lintner, Olivier Peschard, Philippe Mondon, Claire Mas Chamberlin
  • Publication number: 20130058878
    Abstract: Geranylgeranyl-2-propanol compound (GGP) having the following formula (I) is proposed for use according to the present invention as a cosmetic active compound for the prevention and treatment of aging of skin and its appendages. The GGP has a protective action against oxidative stress and free radical, on telomeres and on mitochondria and its activity. In particular, GGP can be used for the treatment of wrinkles, fine lines and visible discontinuities of skin, for the treatment pigmentation disorders.
    Type: Application
    Filed: April 7, 2011
    Publication date: March 7, 2013
    Applicant: SEDERMA
    Inventors: Arnaud Fournial, Philippe Mondon, Olivier Peschard
  • Patent number: RE45992
    Abstract: A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: May 3, 2016
    Assignee: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
    Inventors: Christian Behrens, Sylvie Jorieux, Abdelhakim Kharrat, Khalil Bouayadi, Philippe Mondon, Celine Monnet-Mars